Nitazoxanide

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1081 publications

Fascioliasis presenting as non-resolving liver abscess: Case series from eastern India.

Fascioliasis presenting as non-resolving liver abscess: Case series from eastern India.

Journal: Tropical doctor

Published: May 30, 2026

Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.

Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.

Journal: bioRxiv : the preprint server for biology

Published: May 25, 2026

Terpene-Enriched Nitazoxanide-Loaded Chondrosomes: Aerodynamic Characterization and In Silico Evaluation of Antiviral Activity.

Terpene-Enriched Nitazoxanide-Loaded Chondrosomes: Aerodynamic Characterization and In Silico Evaluation of Antiviral Activity.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 24, 2026

Chronic persistent Norovirus in the immune-compromised host.

Chronic persistent Norovirus in the immune-compromised host.

Journal: Current opinion in infectious diseases

Published: March 13, 2026

Conserved use of tetraspanin CD9 as an entry receptor by rhabdoviruses spanning multiple genera.

Conserved use of tetraspanin CD9 as an entry receptor by rhabdoviruses spanning multiple genera.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 11, 2026

Evaluation of the effect of auranofin alone and in combination with nitazoxanide on Cryptosporidium parvum in immunosuppressed mice.

Evaluation of the effect of auranofin alone and in combination with nitazoxanide on Cryptosporidium parvum in immunosuppressed mice.

Journal: Acta tropica

Published: March 02, 2026

Induction of β-Defensin 1 (DEFB1) via synthetic mRNA reduces Cryptosporidium parvum infection in human intestinal cells.

Induction of β-Defensin 1 (DEFB1) via synthetic mRNA reduces Cryptosporidium parvum infection in human intestinal cells.

Journal: The Journal of infectious diseases

Published: February 16, 2026

Chronic norovirus infection in a patient with Good's syndrome resolved after fecal microbiota transplantion and improved nutrional status.

Chronic norovirus infection in a patient with Good's syndrome resolved after fecal microbiota transplantion and improved nutrional status.

Journal: Infectious diseases (London, England)

Published: February 13, 2026

Promising Drug Repurposing Candidates Targeting Free-Living Amoebae: A Systematic and Critical Review of Laboratory-Based Evidence.

Promising Drug Repurposing Candidates Targeting Free-Living Amoebae: A Systematic and Critical Review of Laboratory-Based Evidence.

Journal: Pathogens (Basel, Switzerland)

Published: February 13, 2026

Nitazoxanide Exhibits Schistosomicidal Activity Against Schistosomula and Adult Schistosoma mansoni and Influences Praziquantel-Associated Outcomes.

Nitazoxanide Exhibits Schistosomicidal Activity Against Schistosomula and Adult Schistosoma mansoni and Influences Praziquantel-Associated Outcomes.

Journal: Acta parasitologica

Published: February 11, 2026

Nitazoxanide-Gold Nanoparticles Combat Carbapenem-Resistant Enterobacteriaceae via Membrane Disruption and Oxidative Stress.

Nitazoxanide-Gold Nanoparticles Combat Carbapenem-Resistant Enterobacteriaceae via Membrane Disruption and Oxidative Stress.

Journal: ACS infectious diseases

Published: February 08, 2026

Aminoglycosides, vancomycin, and metronidazole for people with cirrhosis and hepatic encephalopathy.

Aminoglycosides, vancomycin, and metronidazole for people with cirrhosis and hepatic encephalopathy.

Journal: The Cochrane database of systematic reviews

Published: February 03, 2026

Showing 1-12 of 1,081

Last Updated: 06/30/2026